Berikutnya

Putar otomatis

Defining Progression in Metastatic Kidney Cancer

3 Tampilan • 06/26/23
Membagikan
Menanamkan
administrator
administrator
Pelanggan
0

Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.

Menampilkan lebih banyak
0 Komentar sort Sortir dengan
Komentar Facebook

Berikutnya

Putar otomatis